Dialysis industry news

Stories from the dialysis comunity across the globe.



Bye, Marva! God's awesome creation - Jamaica Observer PDF Print

FOUR days before Marva Sylvia Lewinson, founder of Hope Dialysis Centre, would have celebrated her 50th year, friends and relatives instead gathered to pay final tribute.

Lewinson died on May 4 after suffering a stroke.

Her thanksgiving service was held on May 28 at the Faith Cathedral Deliverance Centre — located off Waltham Park Road in Kingston — headed by Political Ombudsman Bishop Herro Blair.

The service began with the hymn Leaning on the Everlasting Arms followed by a prayer and tributes.

Among those offering tribute was Grace Silvera, LIME Jamaica's regional vice-president, a very close friend of Lewinson.

According to Silvera, their friendship lasted approximately 15 years and the time they were both introduced to each other is "one she will forever treasure".

"Ever so often someone comes into your life and things are never the same. Ever so often you gaze up to the mountains and see the majesty of God's awesome creation. Ever so often the miraculous father puts a little bit more spice and a little bit more spunk into a special human being. He did that with marvellous Marva," said Silvera as she began her tribute.

"Marva, my precious sister, cheerleader and friend. Her generosity knew no bounds," Silvera added before speaking directly of the numerous shopping, travelling and leisure experiences they shared.

"With gospel music pumping in the car and wild animated laughter, we would head off to our daily adventure to the mall," said Silvera. "Marv's delight would be to choose outfits for me [but] I had to caution her that if I purchased some of the outfits she chose, my pastor would read me out of the church," she added to the amusement of the congregation.

Silvera said Lewinson always took pleasure in complimenting her friends about their fashion styles and attire.

"I remember shopping with her once and she chose something for me. After trying it on, she said 'Look at the back! Tun roun! Tun roun! yu look like Michelle Obama.

"It was her pleasure to make sure that her friends were well dressed. So, naturally, if the clothes did not compliment, she would say 'hurry up an' go back in go tek it off," Silvera recalled.

She added that, "Marva was always concerned about the lifestyle of her relatives, friends and colleagues".

Audrey Wynn, sister of the deceased, reiterated that Lewinson's generosity "knew no bounds" she spared no expense and set no limits. Wynn said ever since childhood Lewinson was "brutally, brutally honest, bubbly, vibrant, full of joy, very expressive, complimentary as desired, critical when needed, a dreamer and go-getter with an entrepreneurial mind.

"After working for several companies in Jamaica and the United States of America, she started Jacam Trading, Shop to Earth Online Company and other ventures," said Wynn.

"Marva realised the culmination of a dream when the Hope Dialysis Centre opened for business in February 2009," she added.

Hope Dialysis Centre is reputed to be Kingston's most spacious provider of dialysis care.

Marva was born on May 30 in Kingston and adopted by Aaron and Mary Officer at the age of one. In 1969, she attended Half-Way-Tree Primary School and received her secondary education at Ardenne High School between 1974 and 1979. She was a graduate of Alpha Commercial College. She took several online courses, which led to her complete certification in marketing and management.

Left to mourn Marva's passing are her parents, siblings — Ava, Audrey, Ronald, Wayne, Beaver, and Karen — nieces, nephews, grandnephew, grandniece, a host of other relatives and friends.

...

 
Exelixis Reports Positive Data From Cabozantinib Study In Renal Cell Carcinoma - NASDAQ PDF Print
NASDAQ
(RTTNews.com) - Biotechnology company Exelixis, Inc. (EXEL), revealed positive updated interim data from an ongoing phase 1b trial of cabozantinib in patients with metastatic refractory renal cell carcinoma. The study endpoints included safety,

...

 
Exelixis Reports Positive Data From Cabozantinib Study In Renal Cell Carcinoma - RTT News PDF Print

6/3/2012 2:33 AM ET
(RTTNews) - Biotechnology company Exelixis, Inc. (EXEL: News), revealed positive updated interim data from an ongoing phase 1b trial of cabozantinib in patients with metastatic refractory renal cell carcinoma.

The study endpoints included safety, tolerability, and anti-tumor activity. The data presented are from a cohort of 25 renal cell carcinoma patients enrolled in the phase 1b drug-drug interaction study of cabozantinib at the phase 1 maximum tolerated dose in patients with advanced solid tumors.

All patients had histologically confirmed renal cell carcinoma - with clear cell components - and metastases, were refractory to or had progressed following standard therapy, and had measurable disease per RECIST. Subjects in the trial were administered 140 mg of oral cabozantinib daily and a single dose of rosiglitazone at day 22.

Exelixis indicated the clinical benefit observed with cabozantinib as encouraging, particularly in highly pretreated patients who are refractory to anti-VEGF and anti-mTOR therapies or who have had disease progression while on these agents. Improvements in bone lesions and bone pain were also indicated as encouraging, especially given that bone metastases occur in up to 30 percent of renal cell carcinoma patients.

Objectively, tumor regression was observed in 19 of 21 patients, or 90 percent. Best overall response was determined per RECIST criteria with 7 of 25 patients, or 28 percent, showing a confirmed partial response.

Thirteen additional patients, or 52 percent, had stable disease as their best response, and only a single patient demonstrated evidence of primary refractoriness to cabozantinib with a best overall response of progressive disease. The rate of disease control at week 16 for all 25 patients is 72%.

Kaplan Meier estimate of median progression-free survival was 14.7 months. Median overall survival had not yet been reached after median follow-up of 14.7 months. The estimated 1-year survival rate was 60 percent. Seven patients remain on study and progression free with treatment durations ranging up to 21.8+ months.

Safety results for the study were consistent with those observed in other trials of cabozantinib and with other tyrosine kinase inhibitor therapies. The most frequently reported adverse events were hypophosphatemia, hyponatremia, fatigue, diarrhea, proteinuria, decreased appetite, vomiting, and hand-foot syndrome. Grade 3 and higher adverse events included hypertension in 8% of patients.

Dr. Michael Morrissey, president and chief executive officer of Exelixis, observed, "Taken together, the data demonstrate cabozantinib's potential role to improve care and outcomes for patients with RCC. A randomized phase 2 trial in first-line RCC using a 60 mg dose is planned under our Cooperative Research and Development Agreement with the National Cancer Institute's Cancer Therapy Evaluation Program and should provide further insight into cabozantinib's clinical and commercial potential in this indication."

 1   2   Next Page 

...

 
World Congress of Cardiology poster presentation abstracts (186 page pdf file) PDF Print
Dubai, United Arab Emirates 18 -21 April 2012 -- Poster Presentations From the World Congress of Cardiology Scientific Sessions

...

 
World Congress of Cardiology oral presentation abstracts (83-page pdf file) PDF Print
WCN: 2012 : Dubai, United Arab Emirates18 -21 April 2012 Oral Presentations From the WORLD CONGRESS OF CARDIOLOGY Scientific Sessions.

...

 
<< Start < Prev 601 602 603 604 605 606 607 608 609 610 Next > End >>

Page 609 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.